Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients
- 5 August 2017
- journal article
- pharmacoepidemiology and-prescription
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 73 (11), 1437-1447
- https://doi.org/10.1007/s00228-017-2307-2
Abstract
Purpose The aim of this study was to describe persistence with vitamin K antagonist (VKA) treatment in German atrial fibrillation (AF) patients and to identify factors which may be associated with early discontinuation of VKA therapy. Methods We did a retrospective cohort study based on an anonymized German claims dataset with VKA treatment-naïve AF patients, who received at least one VKA prescription. VKA therapy discontinuation was defined as a gap >180 days. Results We identified 38,076 VKA patients who started a VKA therapy (mean age 76.13 years; 56.08% female; mean CHA2DS2-VASc-Score 4.49; mean Charlson Comorbidity Index (CCI) 3.91). After four quarters since start of VKA treatment, 14,889 (39.10%) of observed patients had discontinued their VKA treatment (after eight quarters: 54.61%). Mean time until treatment discontinuation was 390.55 days. Risk of VKA discontinuation increased with the diagnosis of dementia within the first two quarters of VKA treatment [HR 1.35 (95% CI 1.29–1.40)], diagnosed alcohol or drug abuse in the baseline period [HR 1.25; 95% CI 1.18–1.33)], female gender [HR 1.08; 95% CI 1.05–1.10)], higher age (HR 1.03; 95% CI 1.03–1.03), higher CCI (HR 1.05; 95% CI 1.04–1.05), any prescription of NSAID (HR 1.07; 95% CI 1.04–1.10), and number of surgeries in the first two quarters of VKA treatment (HR 1.05; 95% CI 1.04–1.05). At least one yearly visit to a cardiologist since start of VKA treatment decreased the risk of non-persistence [HR 0.90; 95% CI 0.88–0.93] and a cancer diagnosis in the baseline period (HR 0.92; 95% CI 0.89–0.96). Conclusion Non-persistence related to VKA therapy is common in AF patients. Older more comorbid female patients as well as patients who face surgeries and who do not visit a cardiologist regularly face a higher therapy discontinuation risk.Keywords
Funding Information
- Boehringer Ingelheim Pharma GmbH
This publication has 38 references indexed in Scilit:
- Warfarin Use and Stroke Risk Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care PopulationClinical Therapeutics, 2013
- Patterns of Warfarin Use in Subgroups of Patients with Atrial Fibrillation: A Cross-Sectional Analysis of 430 General Practices in the United KingdomPLOS ONE, 2013
- Patterns and Predictors of Use of Warfarin and Other Common Long-Term Medications in Patients with Atrial FibrillationAmerican Journal of Cardiovascular Drugs, 2012
- Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to EthnicityFrontiers in Pharmacology, 2012
- Warfarin Discontinuation After Starting Warfarin for Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2010
- Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort studyThe Lancet, 2009
- Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial FibrillationJournal of Invasive Cardiology, 2008
- A meta-analysis of the association between adherence to drug therapy and mortalityBMJ, 2006
- The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial FibrillationMayo Clinic Proceedings, 2004